Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonella Francesca Simonetti has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimizing antimicrobial stewardship indicators in the emergency department through the application of days of antibiotic spectrum coverage

    by Jesús Ruiz-Ramos, Pol Duch-Llorach, Laura Gras-Martín, Edurne Fernández-De Gamarra-Martínez, Sergio Herrera-Mateo, Leopoldo Higa-Sansone, María Teresa Álvarez-Albarrán, Maria Alba Rivera-Martínez, Antonella Francesca-Simonetti, Laura Escolà-Vergé

    Background: Antimicrobial prescribing in the emergency department is influenced by short stays, diagnostic uncertainty, and frequent empirical treatment initiation, which complicates the interpretation of antimicrobial use indicators. Days of antibiotic spectrum coverage (DASC) integrates duration and spectrum breadth and may provide complementary information for antimicrobial-use surveillance and stewardship. Methods: Retrospective observational study using aggregated quarterly data from adult ED episodes (January 2021-December 2025). Global antimicrobial use was assessed using Defined Daily Dose (DDD)/100 visits, DDD/100 patient-days, Days of Therapy (DOT)/100 visits, proportion of patients receiving antimicrobials, DASC/100 visits, and DASC/DOT. Trends were analyzed using temporal trend analysis. The main therapeutic groups were evaluated according to their contributions to the total DOT and DASC. Results: During the study period, global antimicrobial consumption decreased for most indicators. DDD/100 visits decreased from 11.28 in 2021 to 8.85 in 2025, DOT/100 visits from 19.08 to 13.31, and the proportion of patients receiving antimicrobials from 12.3% to 9.4%. DASC/100 visits decreased from 132.10 to 94.49 (28.5%). In contrast, DASC/DOT remained stable, with a slight increase from 6.92 to 7.10. Penicillins combined with beta-lactamase inhibitors were the largest contributors to DASC, followed by third-generation cephalosporins, fluoroquinolones, and carbapenems. The reduction in total DASC was mainly driven by decreases in third-generation cephalosporins, fluoroquinolones, metronidazole, and carbapenem exposure, whereas macrolide exposure increased over time. Conclusions: Metrics based on the DASC offer complementary insights to DDD and DOT and may assist antimicrobial stewardship programs in identifying ongoing broad-spectrum prescriptions in emergency care.

  • Open Access

    Adequacy of the Type of Venous Catheter to the Drug Type and Duration of Treatment: A Cross-Sectional Study

    by Esther Moreno-Rubio, Carlos Pérez-López, João Carmezim, David Blancas-Altabella, Antonella F. Simonetti, Silvia Serda Sanchez, Alejandro Rodríguez-Molinero

    Background: Venous catheters are standard devices in clinical practice. However, their use is not exempt from possible errors and complications. In addition, using them effectively is key to avoiding complications such as infection or phlebitis. Objectives: To determine the frequency of appropriate venous catheters chosen based on the drug and treatment duration in hospitalized patients in a region with 154,000 inhabitants. Methods: A cross-sectional design was carried out between 14 and 28 February 2020, in patients with a peripheral or central intravenous catheter admitted to the acute care unit. Variables collected were related to the catheters, patients, and nurses. Results: One hundred and eighty-eight patients were included, with 319 catheters inserted by 68 nurses. Seventeen patients (8.8%) were ruled out due to the lack of data on the medication administered. Finally, data from 171 patients were included in the final analysis, with 297 catheters inserted. Of them, 246 catheters (82.8%) were inadequate. Discussion: In this point-prevalence study, catheter inadequacy affected more than four out of five catheters and was mainly linked to the use of peripheral catheters for high-risk IV medications and/or for treatments extending 7 days or more. Conclusion: The selection of venous catheters in acute care units is not usually adequate since many peripheral catheters are placed in patients who require intravenous medication during a prolonged period or who are receiving risk medication.

  • Effect of a bundle intervention on adherence to quality-of-care indicators and on clinical outcomes in patients with Staphylococcus aureus bacteraemia hospitalized in non-referral community hospitals

    by Francesc Escrihuela-Vidal, Cristina Chico, Beatriz Borjabad González, Daniel Vázquez Sánchez, Ana Lérida, Elisa De Blas Escudero, Montserrat Sanmartí, Laura Linares González, Antonella F Simonetti, Ana Coloma Conde, et al.

    Although a significant number of cases of Staphylococcus aureus bacteraemia (SAB) are managed at non-referral community hospitals, the impact of a bundle-of-care intervention in this setting has not yet been explored. We performed a quasi-experimental before–after study with the implementation of a bundle of care for the management of SAB at five non-referral community hospitals and a tertiary care university hospital. Structured recommendations for the five indicators selected to assess quality of care were provided to investigators before the implementation of the bundle and monthly thereafter. Primary endpoints were adherence to the bundle intervention and treatment failure, defined as death or relapse at 90 days of follow-up. One hundred and seventy patients were included in the pre-intervention period and 103 in the intervention period. Patient characteristics were similar in both periods. Multivariate analysis controlling for potential confounders showed that performance of echocardiography was the only factor associated with improved adherence to the bundle in the intervention period (adjusted OR 2.13; 95% CI 1.13–4.02). Adherence to the bundle, performance of follow-up blood cultures, and adequate duration of antibiotic therapy for complicated SAB presented non-significant improvements. The intervention was not associated with a lower rate of 90 day treatment failure (OR 1.11; 95% CI 0.70–1.77). A bundle-of-care intervention for the management of SAB at non-referral community hospitals increased adherence to quality indicators, but did not significantly reduce rates of 90 day mortality or relapse.


  • Open Access

    Whole-Blood Gene Expression Profiles Associated with Mortality in Community-Acquired Pneumonia

    by Diego Viasus, Antonella F. Simonetti, Lara Nonell, Oscar Vidal, Yolanda Meije, Lucía Ortega, Magdalena Arnal, Marta Bódalo-Torruella, Montserrat Sierra, Alexander Rombauts, et al.

    (1) Background: Information regarding gene expression profiles and the prognosis of community-acquired pneumonia (CAP) is scarce. We aimed to examine the differences in the gene expression profiles in peripheral blood at hospital admission between patients with CAP who died during hospitalization and those who survived. (2) Methods: This is a multicenter study of nonimmunosuppressed adult patients who required hospitalization for CAP. Whole blood samples were obtained within 24 h of admission for genome-expression-profile analysis. Gene expression profiling identified both differentially expressed genes and enriched gene sets. (3) Results: A total of 198 samples from adult patients who required hospitalization for CAP were processed, of which 13 were from patients who died. Comparison of gene expression between patients who died and those who survived yielded 49 differentially expressed genes, 36 of which were upregulated and 13 downregulated. Gene set enrichment analysis (GSEA) identified four positively enriched gene sets in survivors, mainly associated with the interferon-alpha response, apoptosis, and sex hormone pathways. Similarly, GSEA identified seven positively enriched gene sets, associated with the oxidative stress, endoplasmic reticulum stress, oxidative phosphorylation, and angiogenesis pathways, in the patients who died. Protein–protein-interaction-network analysis identified FOS, CDC42, SLC26A10, EIF4G2, CCND3, ASXL1, UBE2S, and AURKA as the main gene hubs. (4) Conclusions: We found differences in gene expression profiles at hospital admission between CAP patients who died and those who survived. Our findings may help to identify novel candidate pathways and targets for potential intervention and biomarkers for risk stratification.


  • Open Access

    Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial—a trial protocol

    by Alexander Rombauts, Gabriela Abelenda-Alonso, Antonella Francesca Simonetti, Guillermo Verdejo, Yolanda Meije, Lucia Ortega, Mercedes Clemente, Jordi Niubó, Yolanda Ruiz, Carlota Gudiol, et al.

    Background: Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. Methods: This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. Discussion: If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP. Trial registration: European Clinical Trials Database (EudraCT) 2018-003117-18. Registered on 12 April 2019. ClinicalTrials.gov NCT04071041. Registered on 27 August 2019


  • Predictors for individual patient antibiotic treatment effect in hospitalized community-acquired pneumonia patients

    by A.F. Simonetti, C.H. van Werkhoven, V.A. Schweitzer, D. Viasus, J. Carratalà, D.F. Postma, J.J. Oosterheert, M.J.M. Bonten


  • PET/CT added to Duke criteria facilitates diagnosis and monitoring of long-term suppressive therapy of prosthetic endocarditis

    by Pedro Puerta-Alcalde, Guillermo Cuervo, Antonella F. Simonetti, Laura Gracia-Sánchez, Daniel Ortiz, Carolina Garcia-Vidal

    (2017). PET/CT added to Duke criteria facilitates diagnosis and monitoring of long-term suppressive therapy of prosthetic endocarditis. Infectious Diseases: Vol. 49, No. 9, pp. 698-701.


  • Toxoplasma myocarditis

    by Guillermo Cuervo, Antonella F. Simonetti, Oriol Alegre, Jose Carlos Sanchez-Salado, Daniel Podzamczer


  • Monocyte HLA-DR expression in community-acquired pneumonia hospitalized patients

    by Antonella Francesca Simonetti

    Welcome to the largest platform for early-stage research